The combination of talquetamab-tgvs and pomalidomide achieved an 85.7% objective response rate in relapsed/refractory multiple myeloma patients. Median progression-free survival was 25.8 months, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback